% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{McCullough:279900,
      author       = {McCullough, Austin and Chen, Charles D and Gordon, Brian A
                      and Joseph-Mathurin, Nelly and Jack, Clifford R and Koeppe,
                      Robert and Hornbeck, Russ and Koudelis, Deborah and McKay,
                      Nicole S and Hobbs, Diana A and Flores, Shaney and Keefe,
                      Sarah J and Aggarwal, Neelum T and Allegri, Ricardo F and
                      Berman, Sarah B and Bird, Thomas and Black, Sandra E and
                      Brooks, William S and Chhatwal, Jasmeer P and Day, Gregory S
                      and Farlow, Martin R and Fox, Nick C and Gauthier, Serge and
                      Honig, Lawrence S and Hsiung, Ging-Yuek and Jucker, Mathias
                      and Levin, Johannes and Masellis, Mario and Masters, Colin
                      and Mendez, Patricio Chrem and Ringman, John M and Snider, B
                      Joy and Salloway, Stephen and Schofield, Peter R and
                      Shimada, Hiroyuki and Suzuki, Kazushi and van Dyck,
                      Christopher H and Klein, Gregory and Clifford, David B and
                      Cruchaga, Carlos and Hassenstab, Jason and Li, Yan and
                      McDade, Eric and Mills, Susan and Morris, John C and Perrin,
                      Richard J and Supnet-Bell, Charlene and Wang, Guoqiao and
                      Xiong, Chengjie and Bateman, Randall J and Benzinger, Tammie
                      L S},
      collaboration = {Team, DIAN-TU Study},
      title        = {{R}egional effects of gantenerumab on neuroimaging
                      biomarkers in the {DIAN}-{TU}-001 trial.},
      journal      = {Alzheimer's and dementia},
      volume       = {21},
      number       = {7},
      issn         = {1552-5260},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DZNE-2025-00860},
      pages        = {e70347},
      year         = {2025},
      abstract     = {Monoclonal anti-amyloid therapies are now accessible, but
                      how these treatments influence changes within the brain is
                      still not clear. We investigated overall and regional change
                      in amyloid removal, glucose metabolism, and atrophy in trial
                      participants with dominantly inherited Alzheimer's disease
                      (DIAD).In the DIAN-TU-001 trial, 92 carriers received
                      gantenerumab or placebo and underwent serial neuroimaging
                      assessments including [11C]-Pittsburgh compound-B (PiB)
                      positron emission tomography (PET),
                      [18F]-fluoro-2-deoxyglucose (FDG) PET, and magnetic
                      resonance imaging (MRI).Gantenerumab significantly reduced
                      PiB-PET uptake overall and in most regions and showed no
                      changes in FDG-PET or MRI measures. Drug effects were
                      associated with baseline PiB-PET uptake, and the largest
                      effects occurred in medial regions.Treated DIAD
                      participants, and especially those with higher amyloid
                      burden, showed a decrease in PiB-PET uptake, which was more
                      pronounced in the basal ganglia and medial frontal
                      structures. These results may inform patient response and
                      future drug trial design.Gantenerumab unevenly decreased Aβ
                      burden as measured by PiB-PET across brain regions. The
                      strongest decrease in PiB-PET uptake was in basal ganglia
                      and medial frontal structures. Variable drug effect on Aβ
                      was partly due to the amount of burden present before
                      treatment. There was no regional effect on FDG-PET
                      metabolism or MRI volumetrics after 4 years.},
      keywords     = {Humans / Alzheimer Disease: drug therapy / Alzheimer
                      Disease: diagnostic imaging / Alzheimer Disease: genetics /
                      Alzheimer Disease: pathology / Positron-Emission Tomography
                      / Male / Female / Magnetic Resonance Imaging / Brain:
                      diagnostic imaging / Brain: drug effects / Brain: pathology
                      / Brain: metabolism / Antibodies, Monoclonal, Humanized:
                      therapeutic use / Antibodies, Monoclonal, Humanized:
                      pharmacology / Neuroimaging / Middle Aged / Biomarkers:
                      metabolism / Thiazoles / Fluorodeoxyglucose F18 / Aniline
                      Compounds / Aged / Amyloid beta-Peptides: metabolism /
                      DIAN‐TU (Other) / FDG‐PET (Other) / MRI measures (Other)
                      / PET (Other) / amyloid targeted monoclonal antibody (Other)
                      / autosomal dominant Alzheimer's disease (ADAD) (Other) /
                      dominantly inherited Alzheimer's disease (DIAD) (Other) /
                      gantenerumab (Other) / imaging outcomes (Other) / regional
                      PiB‐PET uptake (Other) / regional variability (Other) /
                      Antibodies, Monoclonal, Humanized (NLM Chemicals) /
                      gantenerumab (NLM Chemicals) / Biomarkers (NLM Chemicals) /
                      Thiazoles (NLM Chemicals) / Fluorodeoxyglucose F18 (NLM
                      Chemicals) / Aniline Compounds (NLM Chemicals) /
                      2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (NLM
                      Chemicals) / Amyloid beta-Peptides (NLM Chemicals)},
      cin          = {AG Jucker / AG Levin / Clinical Research (Munich)},
      ddc          = {610},
      cid          = {I:(DE-2719)1210001 / I:(DE-2719)1111016 /
                      I:(DE-2719)1111015},
      pnm          = {352 - Disease Mechanisms (POF4-352) / 353 - Clinical and
                      Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-352 / G:(DE-HGF)POF4-353},
      experiment   = {EXP:(DE-2719)DIAN-20090101},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40660741},
      doi          = {10.1002/alz.70347},
      url          = {https://pub.dzne.de/record/279900},
}